Navigation Links
FDA Approves BENLYSTA® for Lupus in Breakthrough for Millions of Sufferers
Date:3/9/2011

NEW YORK, March 9, 2011 /PRNewswire-USNewswire/ -- The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations welcome the U.S. Food and Drug Administration's (FDA) historic approval of BENLYSTA® (belimumab) for systemic lupus erythematosus (lupus), launching the first safe and effective treatment for lupus in more than half a century.

"This is a moment of enormous relief for people with lupus, and a landmark achievement for the nation's scientists, doctors and industry investigators searching for new answers to lupus," said Margaret G. Dowd, president of the Lupus Research Institute, an organization uniquely dedicated to pioneering discovery through novel research in lupus. "BENLYSTA's winding path to FDA approval is a triumph for the dedicated pursuit of innovative science and smart trial design in achieving solid results in the complex autoimmune disease of lupus."

The FDA announced today that BENLYSTA, developed by Human Genome Sciences (HGS) and GlaxoSmithKline (GSK), is approved for treatment of people with active systemic lupus. This decision followed its Arthritis Advisory Committee's 13-2 vote on November 16, 2010 to recommend the drug's approval.  

The development of BENLYSTA stems from the scientific discovery of a new immune system molecule, BLyS, which revealed a critical new pathway that can be manipulated to treat lupus.  BENLYSTA is founded on novel, fundamental science from industry and academia that explores a range of disease pathways and mechanisms, much like the studies that the LRI has been supporting for a decade.

"With BENLYSTA, physicians can now prescribe an effective new agent to manage the signs and symptoms of lupus, and improve the quality of life of their patients," said David S. Pisetsky, M.D., Ph.D., Professor of Medicine and Immunology at Duke University Medical Center and a member of the LRI Scientific Advisory Board.  

"Furthermore, the approval provides important lessons for the lupus research field," said Dr. Pisetsky. "The trial design of the BENLYSTA studies, including the use of a composite outcome measure to assess efficacy, is a major innovation. The developers have taken a new pathway for drug research in lupus, which hopefully, will encourage other companies to rededicate themselves to innovation to reduce and eventually wipe out the burden of this serious autoimmune disease."

"The approval of BENLYSTA means good news for patients like me, hopefully reducing the seemingly endless number of medications with harsh side effects we need to take to stay alive," said Sabrina Nixon, an author and single mother of two from Chicago who was diagnosed with lupus in 2004.

"We thank the hundreds of people with lupus who enrolled and took part in these important BENLYSTA trials," said Dowd. The LRI assists in educating people with lupus about participating in clinical trials to bring safe and effective treatments to market.  To learn more, visit www.LupusTrials.org.

About Lupus

Lupus—systemic lupus erythematosus—is a chronic and often disabling autoimmune disease that is estimated to affect more than 1.5 million Americans.  Ninety percent of people living with lupus are women, with the majority being of childbearing age. People with lupus suffer from symptoms including fever, intense fatigue and exhaustion, joint pains, cognitive problems and skin rashes.  No two cases of lupus are alike, and the effects of the disease can range from kidney disease, premature heart disease, stroke or lung inflammation. There is no known cause or cure for lupus, and no new treatments have been approved for lupus in over 50 years.  For some patients, current treatments can often be toxic and more damaging than the disease itself.

About the Lupus Research Institute

The Lupus Research Institute (LRI) is the nation's only nonprofit organization solely dedicated to novel research in lupus, with the belief that innovative research is the key to finding safer and more effective treatments and a cure for lupus.  In late 1999, as 1.5 million Americans faced the pain and devastation of lupus, patients, families and the nation's leading researchers came together to establish the LRI. With a bold approach and rigorous standards, such as funding innovative research approaches, recruiting new scientists to the field and driving translation of science into the clinic, the LRI is making the breakthroughs that spell compelling new hope for patients worldwide who suffer from this devastating autoimmune illness.

Click here to learn more about the Lupus Research Institute.  


'/>"/>
SOURCE Lupus Research Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)...  West Pharmaceutical Services, Inc. (NYSE: WST ... 2017 and updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, ... Net sales at constant currency (organic) grew by 3.9%. ... compared to $0.60 in the prior-year quarter. Second-quarter 2017 ...
(Date:7/26/2017)... Aesthetics, a leading medical aesthetic clinic in Singapore ... skin conditions from the inside. The natural process of ... skin becomes more transparent due to the thinning of the epidermis. Over ... the sun contributes to aging skin, causing age spots and other ... ...
(Date:7/26/2017)... 26, 2017 The Galien Foundation announced ... USA Award Nominees. Counted among the global ... recognizes outstanding biomedical and technology product achievement that improves the ... qualify, each candidate must be U.S. Food and Drug Administration ... demonstrate tremendous potential to impact human health. Sales data are ...
Breaking Medicine Technology:
(Date:7/27/2017)... Plano, TX (PRWEB) , ... July 27, 2017 ... ... technology and outsourced services, announces the internal promotion of Elrene Clinkscales to Vice ... Operations – Claims & Remittance Management, reporting to Derek Morkel, chief executive officer ...
(Date:7/27/2017)... ... 2017 , ... Team Novo Nordisk, the world’s first all-diabetes professional cycling team, ... a stagiaire for the remainder of the 2017 season. One of our best development ... Tour of Utah. , “Every season we are excited to move an athlete from ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: Ashley D. Beall, ... in drug therapy for patients living with relapsing and primary multiple sclerosis that ... cell targeted therapy that has been proven to significantly reduce signs of disease ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are dentists and we thought there ... Jose, Calif., “so we invented the MAGNETIC/ LOCK BRACKETS.” , The patent-pending MAGNETIC/ LOCK ... In doing so, it offers an effective alternative to traditional braces. As a result, ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be ... for patients to schedule an appointment online in real time,” said Keith English, LocalMed ... Smiles provider directory will bring more Six Month Smiles patients to their providers.” , ...
Breaking Medicine News(10 mins):